Magnetic Resonance Spectroscopy Studies of the Glutamatergic System in Mood Disorders: A Pathway to Diagnosis, Novel Therapeutics, and Personalized Medicine?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Recent methodological developments in the fields of neuroimaging, genetics, and basic neuroscience are reconceptualizing research into mental disorders (1). In particular, findings from functional, structural, and neurochemical imaging studies, along with discoveries from genome-wide association studies have provided novel and promising leads regarding neural circuitry dysfunction in mood disorders. However, translating this accumulating knowledge into practical methods for defining biologically driven disease categories, selecting the most appropriate treatment for a specific patient (i.e., personalized medicine), and developing novel treatments remain major unresolved challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationWalter, M., Henning, A., Grimm, S., Schulte, R. F., Beck, J., Dydak, U., Schnepf, B., Boeker, H., Boesiger, P., & Northoff, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.39 · Cited by 306 · cited 1×
“instance, glutamatergic abnormalities appear to be more pronounced in patients with melancholic depression (5) or with a high degree of anhedonia (6) compared with patients with atypical depression or little anhedonia.”
Background
Cited by
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Self-citationMathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“[45] Combining MRS with other imaging techniques – such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET) or magnetoencephalography (MEG) – is already helping investigators integrate data across multiple sources and may ultimately help identify glutamatergic abnormalities that could s…”
BackgroundSelf-citationArnone, D., Mumuni, A. N., Jauhar, S., Condon, B., & Cavanagh, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.016 · Cited by 150
“Of interest, carbon-13 MRS methodologies may be better suited to investigate cross cellular exchanges involved in the glutamate/glutamine cycle (Salvadore and Zarate, 2010)(Ongür et al., 1998).”
BackgroundNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Self-citationIntrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“7T), and exposure to medication (94), pairing 1H-MRS with functional neuroimaging modalities may partially mitigate the challenge of determining the neurochemical source of signal, providing an insight into the role of glutamate in the circuits involved in the pathophysiology of depression (95).”
Background
Metadata
- Authors
- Salvadore, G., & Zarate, C. A.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 68
- Issue
- 9
- Pages
- 780-782
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2086610812
- Cited by
- 23
- References
- 2
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.